This enhancement of cholinergic signaling is particularly relevant given that cholinergic dysfunction is a hallmark of AD, and traditional FDA‐approved treatments primarily target this system through acetylcholinesterase inhibition. The gene discussed is ACHE; the disease is Alzheimer disease.